Amgen has announced it is building a ‘next-generation’ biomanufacturing plant at its West Greenwich campus in Rhode Island.

The first of its kind in the US, the plant will be used to manufacture products for local and international markets and will feature various innovative technologies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Amgen claims that it will be built in half time of a standard plant and will have half the operating costs. This is due to next-generation plants having smaller manufacturing footprints and better environmental benefits such as minimised water and energy consumption and low carbon emissions.

The plant is set to create around 150 manufacturing jobs and about 200 construction and validation jobs.

Amgen Operations executive vice-president Esteban Santos said: “Amgen has three decades of experience in biologics manufacturing, and we are proud of our track record of providing a reliable supply of high-quality medicines for patients around the world.

“We are pleased to build the first commercial scale, next-generation biomanufacturing plant in the US, leveraging Amgen’s capabilities and incorporating the latest technologies.”

“We are pleased to build the first commercial scale, next-generation biomanufacturing plant in the US, leveraging Amgen’s capabilities and incorporating the latest technologies.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Amgen opened its first next-generation biomanufacturing plant in Singapore in 2014.

The company intends to use such production facilities to enable a reliable, fast and flexible increase in manufacturing capabilities and productivity.

The equipment used in the plant is portable, small and disposable, allowing more flexibility and speed when manufacturing multiple medicines.

This smaller footprint means Amgen can quickly respond to changing demands, improving the time taken for medicines to reach patients.